Elizabeth I. Buchbinder

Also affiliated with Dana-Farber Cancer Institute, Global Cancer Institute

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

Nature Medicine(2021)10.1038/s41591-020-01206-4

N/A

4.5DataRank · unranked

525 citations

Donna Leet, Rosa Lundbye Allesøe, Giacomo Oliveira, Shuqiang Li, Adrienne Luoma +36 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9522

N/A

0.326DataRank · unranked

3 citations

Donald P. Lawrence, David F. McDermott, Mofei Liu, Elizabeth I. Buchbinder, Irena Gushterova +14 more

CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3609

N/A

0.293DataRank · unranked

4 citations

James M. Cleary, Justine V. Cohen, Donald P. Lawrence, Elizabeth I. Buchbinder, Anita Giobbie‐Hurder +11 more

Stratified analysis identifies HIF-2 α as a therapeutic target for highly immune-infiltrated melanomas

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.10.29.620300

N/A

0.231DataRank · unranked

3 citations

Kelly P. Burke, Ryan Porter, Lynn Meiger, Peter Fatouros, Jiekun Yang +24 more

Specific oncogene activation of the cell of origin in mucosal melanoma

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.04.22.590595

N/A

0.168DataRank · unranked

2 citations

Jiajia Chen, Emily Robitschek, Chloé S. Baron, Constance Wu, Aikaterini Dedeilia +17 more

Specific oncogene activation of the cell of origin in mucosal melanoma

Nature Communications(2025)10.1038/s41467-025-61937-1

N/A

0.107DataRank · unranked

1 citations

Jiajia Chen, Chloé S. Baron, Kaiwen Sun, Emily Robitschek, Alicia M. McConnell +18 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma

Cell(2025)10.1016/j.cell.2025.06.019

N/A

0DataRank · unranked

30 citations

Derin B. Keskin, Chloe Ran Tu, Cleo Forman, Allison P. Vanasse, Haley E. Sax +39 more

Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor–associated acute interstitial nephritis

Kidney International(2025)10.1016/j.kint.2025.05.029

N/A

0DataRank · unranked

13 citations

Kavita Mistry, Firasat M Alikhan, Sherley M. Mejia, Sagar Sadarangani, Andrew Cao +22 more

Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1416

N/A

0DataRank · unranked

71 citations

David Liu, Diana Miao, Bart Lutterbach, Alexander L. DeVine, Chenyu Lin +19 more

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade

Haematologica(2020)10.3324/haematol.2020.258426

N/A

0DataRank · unranked

5 citations

Adam S. Sperling, Christopher J. Gibson, Olga Pozdnyakova, Waihay J. Wong, Michael P. Manos +5 more

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Scientific Reports(2020)10.1038/s41598-020-73466-6

N/A

0DataRank · unranked

4 citations

Elizabeth A. Sigworth, Adrianne H. Wu, Jess Behrens, Shervin Etemad, Seema Nagpal +28 more

S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10090

N/A

0DataRank · unranked

1 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +8 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps9585

N/A

0DataRank · unranked

3 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +9 more

Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer

Seminars in Arthritis and Rheumatism(2023)10.1016/j.semarthrit.2023.152335

N/A

0DataRank · unranked

19 citations

Senada Arabelovic, Xiaosong Wang, Taylor Wolfgang, Kazuki Yoshida, Grace Qian +11 more